Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Larimar Therapeutics, Inc. LRMR
$5.13
-$0.14 (-2.66%)
На 18:02, 12 мая 2023
-22.03%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
220240228.00000000
-
week52high
6.85
-
week52low
1.53
-
Revenue
0
-
P/E TTM
-6
-
Beta
0.17055300
-
EPS
-1.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| William Blair | Market Perform | Outperform | 15 февр 2022 г. |
| William Blair | Outperform | 01 февр 2021 г. | |
| William Blair | Outperform | Market Perform | 19 сент 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 сент 2022 г. |
| Guggenheim | Buy | 19 окт 2022 г. | |
| Citigroup | Neutral | 13 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BEN-MAIMON CAROLE | A | 325000 | 325000 | 31 янв 2023 г. |
| BEN-MAIMON CAROLE | A | 261829 | 205000 | 31 янв 2023 г. |
| Celano Michael | A | 120000 | 120000 | 31 янв 2023 г. |
| Celano Michael | A | 107746 | 76000 | 31 янв 2023 г. |
| Flynn James E | A | 2777777 | 2777777 | 16 сент 2022 г. |
| Flynn James E | A | 4721197 | 2777777 | 16 сент 2022 г. |
| Flynn James E | A | 4721200 | 2777777 | 16 сент 2022 г. |
| Flynn James E | A | 4721183 | 2777777 | 16 сент 2022 г. |
| Hamilton Thomas Edward | A | 507590 | 317460 | 16 сент 2022 г. |
| BEN-MAIMON CAROLE | A | 56829 | 31746 | 16 сент 2022 г. |
Новостная лента
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
GlobeNewsWire
21 ноя 2022 г. в 16:05
BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company's presentation will take place on Thursday, December 1, 2022, at 10:10 AM ET.
5 Stocks to Bet on in an Innovation-Driven Drug Industry
Zacks Investment Research
20 окт 2022 г. в 12:02
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
New Strong Buy Stocks for October 7th
Zacks Investment Research
07 окт 2022 г. в 09:02
PBR, HP, MNTK, LRMR and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2022.
What Makes Larimar (LRMR) a New Buy Stock
Zacks Investment Research
28 июл 2022 г. в 13:16
Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).